1. Home
  2. FAF vs IMVT Comparison

FAF vs IMVT Comparison

Compare FAF & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First American Corporation (New)

FAF

First American Corporation (New)

N/A

Current Price

$67.18

Market Cap

6.3B

Sector

Finance

ML Signal

N/A

Logo Immunovant Inc.

IMVT

Immunovant Inc.

N/A

Current Price

$24.20

Market Cap

5.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FAF
IMVT
Founded
1889
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FAF
IMVT
Price
$67.18
$24.20
Analyst Decision
Buy
Buy
Analyst Count
4
9
Target Price
$75.75
$29.13
AVG Volume (30 Days)
1.1M
1.4M
Earning Date
02-11-2026
02-06-2026
Dividend Yield
3.28%
N/A
EPS Growth
428.61
N/A
EPS
4.65
N/A
Revenue
$7,087,600,000.00
N/A
Revenue This Year
$19.04
N/A
Revenue Next Year
$7.13
N/A
P/E Ratio
$14.43
N/A
Revenue Growth
20.70
N/A
52 Week Low
$53.09
$12.72
52 Week High
$68.64
$27.80

Technical Indicators

Market Signals
Indicator
FAF
IMVT
Relative Strength Index (RSI) 66.51 50.20
Support Level $62.58 $23.90
Resistance Level $66.70 $26.82
Average True Range (ATR) 1.80 1.18
MACD 0.49 -0.20
Stochastic Oscillator 92.94 53.11

Price Performance

Historical Comparison
FAF
IMVT

About FAF First American Corporation (New)

First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: